Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

被引：0
|
作者：
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
机构：
[1] Massachusetts General Hospital and Harvard Medical School,Translational Discovery & Development
[2] Moffitt Cancer Center-McKinley Outpatient Clinic,undefined
[3] Mayo Clinic,undefined
[4] Sarah Cannon Research Institute/Tennessee Oncology,undefined
[5] Icahn School of Medicine at Mount Sinai,undefined
[6] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[7] Florida Cancer Specialists-South/Sarah Cannon Research Institute,undefined
[8] GSK,undefined
[9] Ludwig Center at Harvard,undefined
[10] EQRx,undefined
[11] Boston Pharmaceuticals,undefined
[12] Alkermes Incorporated,undefined
[13] Bicycle Therapeutics,undefined
来源：
Nature Cancer | 2022年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1138 / 1138
相关论文
共 50 条
  • [31] Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
    Gelmon, Karen A.
    Fasching, Peter A.
    Couch, Fergus J.
    Balmana, Judith
    Delaloge, Suzette
    Labidi-Galy, Intidhar
    Bennett, James
    McCutcheon, Susan
    Walker, Graham
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 68 - 77
  • [32] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [33] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [34] Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: results from three phase 3 niraparib trials
    Gonzalez-Martin, Antonio
    Grabowski, Jacek
    Matulonis, Ursula
    Korach, Jacob
    Mirza, Mansoor
    Moore, Kathleen
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 120 - 120
  • [35] Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
    Pan, Junjie
    Ren, Ning
    Ren, Lanqi
    Yang, YiBei
    Xu, Qiaoping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [36] Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
    Roudini, Kamran
    Mirzania, Mehrzad
    Yavari, Tahereh
    Seyyedsalehi, Monireh Sadat
    Nahvijou, Azin
    Zebardast, Jayran
    Saadat, Mina
    Khajeh-Mehrizi, Ahmad
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (04) : 206 - 215
  • [37] PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Conte, Benedetta
    Martel, Samuel
    Maurer, Christian
    Tagliamento, Marco
    Viglietti, Giulia
    Del Mastro, Lucia
    De Azambuja, Evandro
    Lambertini, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study
    Ahn, Hee Kyung
    Kim, Jee Hung
    Kim, Mirae
    Park, Seri
    Koh, Su-Jin
    Sohn, Joo Hyuk
    Kang, Myoung Joo
    Jung, Kyung Hae
    Lee, Kyoung Eun
    Lee, Jieun
    Koh, Sung Ae
    Chae, Yee Soo
    Byun, Jae Ho
    Park, In Hae
    Kim, Hee-Jun
    Kim, Jee Hyun
    Kim, Han Jo
    Jung, Joo Young
    Lee, Jung Lim
    Cho, Yoon Young
    Park, Kyong Hwa
    Kim, Ji-Yeon
    Im, Seock-Ah
    Park, Yeon Hee
    CANCER RESEARCH, 2023, 83 (05)
  • [39] Cost-effectiveness for companion BRCA testing and adjuvant olaparib treatment in patients with BRCA mutated high-risk HER2-negative early breast cancer
    Sheppard, E.
    Ma, W.
    Punekar, Y.
    Sagoo, G.
    Nikolova, S.
    VIRCHOWS ARCHIV, 2024, 485 : S347 - S347
  • [40] Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
    Robert S. Miller
    Stella Mokiou
    Aliki Taylor
    Ping Sun
    Katherine Baria
    Breast Cancer Research and Treatment, 2022, 193 : 83 - 94
12345